FDA Approved for RRMM: Pomalidomide (Pomalyst)
SUMMIT, N.J.--(BUSINESS WIRE)--Feb. 8, 2013-- Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration...
Dec 13, 2013
112
NCT01782963: Phase 2 - Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM) (RVD Lite)
RVD Lite NDMM NCT01782963: Phase 2 - Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM) (RVD Lite) This research study is a...
Dec 13, 2013
269
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE) The purpose of this study is to assess the...
Dec 12, 2013
88
NCT01857115: Phase 1/2: EMN - Study of Wkly Carfilzomib, Cyclophosphamide and Dexamethasone In NDMM
wCCyd EMN European Myeloma Network NCT01857115: Phase 1/2: Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly...
Dec 11, 2013
112
NCT01864018: Phase 1/2: Ixazomib Citrate, Cyclophosphamide, and Dexamethasone in NDMM or L C Amyloid
NCT01864018: Phase 1/2: Ixazomib Citrate, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Symptomatic...
Dec 11, 2013
70
NCT01946477: Phase 2 -Pomalidomide Combination With Low-dose Dex +/- Dara in RRMM Myeloma POM MM 014
POM MM 014 Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and...
Dec 7, 2013
65
NCT02002598 : Phase 1 /2 -Carfilzomib + Bendamustine and Dex in New MM
This study is designed to define dose-limiting toxicity and determine preliminary evidence of efficacy of Carfilzomib (CFZ) in...
Dec 6, 2013
204
NCT01775553: Phase 2- High Dose Carfilzomib in Myeloma Patients Who Have Progressed On Standard Dose
NCT01775553: Phase 2: Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib The...
Dec 6, 2013
156
NCT01850524: Phase 3 - TOURMALINE-MM2 - Oral Ixazomib + Lenalidomide/Dex Vs Placebo + Len/Dex NDMM
TOURMALINE-MM2 IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With...
Dec 6, 2013
138
NCT01916252: Phase 3 - Bortezomib, Lenalidomide & IV Busulfan Under 65 - (GEM2012MENOS65) PETHEMA
Phase III study PETHEMA (GEM2012MENOS65) GEM12 MENOS65 PETHEMA/GEM Spanish Myeloma Group GEM (Grupo Español de Mieloma)/PETHEMA (Programa...
Dec 5, 2013
323
NCT01971658: Phase 3: Efficacy Study Comparing VTD Versus VCD as Induction NDMM - IFM2013-04
IFM2013-04 NCT01971658: Phase 3: Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone...
Dec 5, 2013
235
Chemotherapy Basics by Chemocare.com
Chemotherapy Basics by Chemocare.com
Dec 4, 2013
96
NCT01572480: Phase 2: Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
NCT01572480: Phase 2: Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma KRd Multiple myeloma is a blood cancer...
Dec 23, 2012
183
NCT01754402: Phase 1 / 2 - Bendamustine + Pomalidomide + Dex in Relapsed Multiple Myeloma
This study is designed as a phase I-II, open label, dose finding study. Study treatment will be as follows, in 28 day cycles: ...
Dec 21, 2012
244
NCT01665794: Phase 1/2: Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With RRMM
NCT01665794: Phase 1/2: Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma...
Dec 21, 2012
164
NCT01677858: Phase 1/2: Weekly Carfilzomib + Dex for Progressive Multiple Myeloma (CHAMPION 1)
CHAMPION Kd A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma (CHAMPION 1) The study had...
Dec 20, 2012
217
NCT01723020: A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
NCT01723020: A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma A Phase 1 Study Evaluating AMG 232 in...
Dec 14, 2012
84
NCT01729091: Phase 2: Umbilical Cord Blood-Derived NK Cells, Elotuzumab, Len, Melphalan f/b ASCT
NCT01729091: Phase 2: Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by...
Dec 13, 2012
182
NCT01568866: Phase 3 - Carfilzomib and Dex Vs Bortezomib & Dex for Relapsed Myeloma (ENDEAVOR)
The ENDEAVOR Trial KD Vs Vd The primary objective of this study was to compare progression-free survival in patients with multiple...
Dec 12, 2012
473
FDA Approved for RRMM: Carfilzomib (PX-171-003-A1) for relapsed refractory multiple myeloma
SOUTH SAN FRANCISCO, Calif., July 25, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced today that Blood, the...
Dec 12, 2012
130
Nature Video: Immunotherapy: Boosting the immune system to fight cancer
Nature Video: Immunotherapy: Boosting the immune system to fight cancer Learn more: nature video - YouTube
Dec 8, 2012
112
NCT01592370: Phase 1/2: Safety and Effectiveness of Nivolumab and Daratumumab in Multiple Myeloma
NCT01592370: Phase 1/2: An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in...
Dec 8, 2012
97
NCT01734928: Phase 3 - Safety/Efficacy of Pom Bortezomib and Low-dose Dex in relapsed MM (OPTIMISMM)
The OPTIMISMM trial The purpose of this study is to compare the efficacy of the combination of pomalidomide, bortezomib and low dose...
Dec 6, 2012
390
NCT01712789: Phase 3 - Pomalidomide + Dex (Low Dose) Refractory or Relapsed Multiple Myeloma STRATUS
STRATUS RRMM Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed...
Dec 6, 2012
113